PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Clin Lab Med. Author manuscript; available in PMC Dec 1, 2010.
Published in final edited form as:
PMCID: PMC2774466
NIHMSID: NIHMS132107
Respiratory Syncytial Virus Vaccine Development
Yoshihiko Murata, MD PhD
Assistant Professor of Medicine, Division of Infectious Diseases, University of Rochester School of Medicine and Dentistry; and Attending Physician, Infectious Diseases Unit, Rochester General Hospital, Rochester, New York
Corresponding author for proof and reprints: Yoshihiko Murata, MD PhD, Division of Infectious Diseases, Department of Medicine, University of Rochester School of Medicine and Dentistry, 575 Elmwood Avenue, Box 689, Rochester, NY 14642, Yoshihiko_Murata/at/urmc.rochester.edu, Yoshihiko.Murata/at/rochestergeneral.org, 585-922-5068, 585-442-9328 (FAX)
Respiratory syncytial virus (RSV) is a clinically significant cause of respiratory tract disease, especially among high-risk infants and immunocompromised and elderly adults. Despite the burden of disease, there is no licensed prophylactic RSV vaccine. The initial efforts to develop an RSV vaccine involved formalin-inactivated virus preparations that unexpectedly caused vaccine-enhanced disease in clinical trials in RSV-naïve children. Over the last four decades, cautious and deliberate progress has been made towards RSV vaccine development using a variety of experimental approaches (Table 1), including live attenuated strains, vector-based, and viral protein subunit/DNA-based candidates. The scientific rationale, preclinical testing, and clinical development of each of these approaches are reviewed.
Table 1
Table 1
Overview of various experimental approaches to RSV vaccine development.
Keywords: espiratory syncytial virus, vaccine, humoral immunity, cellular immunity, respiratory tract infection
Since its identification in 1956, RSV has been known to be a significant cause of respiratory tract illness in persons of all ages and is the most clinically important cause of lower respiratory tract infections in infants and children1. Following primary RSV infection, which generally occurs by age 2, immunity to RSV remains incomplete and frequent re-infections occur throughout life, with the most severe infections occurring at the extremes of age and among the immunocompromised2. In the United States, RSV is estimated to cause approximately 126,000 annual hospitalizations and approximately 300 deaths among infants younger than 1 yr of age3. Furthermore, RSV accounts for more than 80,000 hospitalizations and more than 13,000 deaths each winter among adults who are elderly or have underlying cardiopulmonary and/or immunosuppressive conditions4. Despite such burden of disease, the number of currently licensed prophylactic and therapeutic agents against RSV infection remains exceedingly limited -- the humanized monoclonal antibody (mAb) palivizumab, which is currently licensed only for use in high-risk infants, and ribavirin that is licensed for use only in the pediatric population1. Because of marked imbalance between the clinical burden of RSV and the available therapeutic and prophylactic options, development of an RSV vaccine remains an unmet medical need.
RSV is an enveloped virus of the Paramyxoviridae family5. Clinical RSV isolates are classified according to antigenic group (A or B) and further subdivided into 5–6 genotypes based on the genetic variability within the viral genome. Each virion contains a non-segmented, negative sense, single-stranded RNA that encodes 11 proteins, eight being structural and three are non-structural (NS1, NS2, M2-2). The viral envelope bears three transmembrane glycoproteins (G, F, SH) as well as the matrix (M) protein. Within the envelope, viral RNA is encapsidated by a transcriptase complex comprised of the N (nucleocapsid), P (phosphoprotein), M2-1 (transcription elongation factor), and L (polymerase) proteins. The early events in RSV replication are: 1) viral attachment to the target cell, a process mediated mainly by the attachment (G) glycoprotein, and 2) membrane fusion and viral penetration into the host cell, processes that require the fusion (F) protein and augmented by the SH protein. Among viral isolates, some RSV-encoded proteins such as F are highly conserved with respect to amino acid (aa) sequence while others such as G display extensive antigenic variation between and within the two major antigenic groups.
The various RSV-encoded proteins have been extensively analyzed with respect to their immunogenicity. Several proteins, including N, M2-1, NS1, and F, bear epitopes that induce cytotoxic T lymphocyte (CTL) responses in murine- and/or human-derived lymphocytes5. In contrast, extensive efforts to identify CTL epitopes in other proteins, including the G protein, have been unfruitful. With regard to humoral response, only antibodies against F or G are neutralizing and confer resistance to RSV upon passive transfer in animal models6, 7. A number of F-specific neutralizing monoclonal antibodies (mAbs) also possess the ability to inhibit viral fusion activity8. One such mAb is palivizumab, a humanized derivative of an anti-F neutralizing mAb that is licensed for prevention of serious RSV illness in high-risk children9.
In the infected host, RSV stimulates a broad range of innate and adaptive immune responses, including chemokine and cytokine secretion, neutralizing humoral and mucosal antibodies, and type 1 and type 2 CD4+ and CD8+ T cells5, 10. These host immune responses, in turn, are thought to be primarily responsible for the clinical manifestations of RSV infections since RSV causes limited cell cytopathology in vivo10. Based on extensive testing in animal models and also from human immunological studies, the phenotypic manifestations and severity of RSV disease are mediated by the fine balance and dynamic interactions among the various chemokine, cytokine, and cellular responses11.
Within the host, cellular and humoral responses appear to play different roles in the protection against and resolution of RSV infection as well as disease pathogenesis. As shown by clinical and preclinical studies with palivizumab, RSV-specific antibodies are sufficient to prevent or limit the severity of infection but not required for clearing primary infection9. However, once RSV infection is established, T cell-mediated responses are necessary to abolish viral replication12. In murine models, passive transfer of CD4+ T-cells and CD8+ CTL eliminates RSV, the latter being more efficacious13. Additionally, T cell responses play key roles in pulmonary pathology during infection, with striking differences noted between Th1 and Th2 CD4+ cells. Interferon-γ (IFN-γ) secreting CD4+ T cells (Th1), with or without associated CD8+ CTL response, clear virus with minimal lung pathology, while viral clearance by IL-4 secreting CD4+ cells (Th2) is associated with more significant pulmonary changes, often marked by eosinophilic infiltration14, 15.
Of profound relevance to vaccine design is the effect of the priming immune response on clinical illness and lung pathology during subsequent RSV infection. Immunization with live RSV or with replicating vectors encoding RSV F protein induces a Th1 dominant response with neutralizing antibody and CD8+ CTL responses that are associated with minimal pulmonary pathology upon virus challenge11, 16. In contrast, immunization with inactivated RSV preparation induces a Th2 dominant response without associated CD8+ CTL but paradoxically leads to increased pathological changes in the lungs17. Interestingly, the administration of RSV G protein as a purified subunit vaccine or even in the context of a replicating vector induces a Th2–dominant response and leads to eosinophilic pulmonary infiltrates and airway hyper-reactivity following virus challenge18. It should be noted that these observations are strikingly reminiscent of the first RSV vaccine studies using formalin-inactivated virus (see below).
Extensive review of RSV replication, pathogenesis, and immune response in animal models and human infections has identified several key issues for RSV vaccine development19. First, the immune system of young infants, the primary population for vaccination, is notable for its immaturity and the presence of maternal anti-RSV antibodies during the first several months of life; in turn, these two factors may negatively affect the emergence of a robust immune response following vaccination. Second, a successful RSV vaccine must be able to target both A and B subtypes; this requirement is hampered by the genetic variability of RSV genome, and particularly of the RSV G protein, as well as the post-translational glycosylation of F and G proteins. Third, immunity against RSV remains incomplete after natural infection and thus annual vaccinations may be required; the goal of such vaccination programs is to prevent severe lower respiratory tract infections. It is possible that two vaccines – one for the RSV-naïve, infant population and another for RSV-experienced adults – may be required. Lastly, in the historical context of formalin-inactivated RSV vaccine trials (see below), the safety profile of RSV vaccine candidates will need to be well established during preclinical and clinical development.
Prior and current RSV vaccine approaches
Various strategies have been pursued to develop an effective and safe RSV vaccine including: 1) inactivated virus preparations; 2) live attenuated/genetically engineered viruses; 3) purified RSV protein subunit vaccine preparations; 4) vector-based vaccine candidates; and 4) DNA-based vaccines. Each approach is summarized below.
The first vaccine trial, performed nearly 40 years ago, employed a formalin-inactivated whole virus preparation (FI-RSV) with aluminum hydroxide adjuvant20. Strikingly, FI-RSV failed to induce neutralizing antibodies or protect vaccinated infants and unexpectedly led to enhanced disease severity when RSV infection occurred during the subsequent winter; in one center, more than 80% of the recipients of the FI-RSV vaccine required hospitalization as compared to only 5% of RSV-infected control subjects2123. Such disease enhancement, or potentiation, in which the vaccination paradoxically worsened the clinical course of subsequent RSV infection, appears to be due to altered host immune response against RSV.
The lack of protective efficacy of FI-RSV is likely due to one or more factors, including the development of poorly neutralizing antibodies against RSV-encoded epitopes, perhaps due to denaturation of such epitopes; incomplete affinity maturation of anti-RSV antibodies; and lack of a robust anti-RSV CTL response as shown in animal studies2426. The potentiation phenomenon appears to be due to a vaccine-induced priming and delayed hypersensitivity response involving Th2 CD4+ T-cells26. It should be noted that a clinical trial using parenterally administered live virus also failed to provide protection, although enhanced RSV disease did not occur27.
The major goal of generating live-attenuated RSV strains is to create a vaccine with the capacity to elicit a broad, protective immune response without significant clinical illness. Such studies of live-attenuated RSV strains began with the isolation of RSV strains that are able to replicate better at < 37°C (i.e. at temperatures similar to those within the upper respiratory tract) than at 37°C (i.e. within the lower respiratory tract), thereby reducing the risk of serious lower respiratory tract illness. To date, such strategies include: 1) serial viral passages to identify and characterize cold-passaged (cp) strains; 2) chemical mutagenesis to generate mutant RSV strains with temperature-sensitive (ts) phenotypes; and 3) reverse genetics to engineer recombinant RSV strains bearing attenuated phenotype while maintaining genetic stability28.
Extensive serial passage at progressively lower temperatures led to the isolation of cpRSV, which remained replication-competent at 26°C29. Derivatives of cpRSV strains were generated by mutagenesis with 5-fluorouracil and one such derivative, cpts248/404, was deemed sufficiently attenuated for clinical testing in RSV-naïve infants (1–2 months old)30. In such a study, >80% of infant subjects were infected by the attenuated RSV strain and had a ≥ 4-fold increase in RSV-specific IgA levels following challenge. Moreover, the majority of vaccine recipients were resistant to infection by a second dose of the vaccine strain given one month after the primary challenge. However, > 70% of 1–2 month old infant vaccine recipients developed nasal congestion at the time of peak viral titer. Thus, the phenotype of cpts248/404 strain was deemed as insufficiently attenuated for use in very young, RSV-naïve infants. However, the replication of this viral strain appeared to be unrelated to the level of maternal antibodies among vaccinees and there was no obvious evidence of vaccine-enhanced RSV disease in post-study follow-up.
Another group of biologically derived RSV mutants was isolated from successive rounds of chemical mutagenesis of the group A strain RSS-2 and selection for ts phenotype. The final derivative, ts1C, was tested in intranasal challenge in a small study involving 22 healthy young adults31. Following such administration, 30% of vaccine recipients exhibited viral shedding and among this subgroup, none demonstrated clinical signs and symptoms of respiratory diseases. Following intranasal challenge, nearly 70% exhibited a ≥ 2-fold increase in serum titers of RSV-neutralizing antibodies, with the greater increases trending to correlate with lower pre-vaccination anti-RSV titers. Thus, this small-scale study provided support for increased study of this RSV strain in the adult population.
The advent of reverse genetics and elucidation of structure-function relationships for the majority of RSV-encoded proteins have led to the generation and testing of second-generation live-attenuated vaccine candidates. To this end, the genomic RNA of live-attenuated RSV strains that were biologically derived and/or chemically mutagenized were sequenced to identify nucleotide changes potentially associated with the attenuated phenotype3234. Such nucleotide changes, e.g. mutation affecting aa 1030 of the L protein, have then been engineered into existing RSV strains in hopes of further attenuation. Deletions of RSV genes have also been attempted for further attenuation and/or potentially increasing host response; for example, the deletion of the SH gene causes up to 10 fold decrease in RSV replication in primates, while the deletion of NS1 and/or NS2 genes may increase the expression of type I interferon and thus potentially increase immunogenicity in vaccinees35, 36.
Based on the above genetic manipulations, at least two lineages of second-generation, live-attenuated RSV vaccine candidates have been generated. The first is rA2cp248/404/1030ΔSH, in which the cp248/404 was engineered to bear the L protein aa 1030 mutation as well as the deletion of the SH gene32. When evaluated in RSV-naïve, very young infants (1–2 months old), ≥ 4 fold increase in anti-RSV antibodies were noted in 44% of infants previously uninfected with RSV, and the second dose of the vaccine strain given within two months of the priming dose was significantly restricted, indicating that protective immunity was achieved in a majority of RSV-naïve vaccine recipients37. However, the rA2cp248/404/1030ΔSH strain appears to exhibit some degree of genetic and phenotypic instability during replication, likely necessitating further manipulations for additional vaccine testing37. The second line of reverse genetics-mediated RSV vaccine candidate is comprised of rA2cp derivative bearing deletions in the NS2 gene, i.e. rA2cpΔNS2, rA2cp530/1009ΔNS2, and rA2cp248/404ΔNS238. In limited clinical studies, the first of the three strains appeared to be overly attenuated in adults, while the latter two were over-attenuated for use in the pediatric population38. Thus, derivatives of RSV strains deleted for NS2 are being studied for additional genetic manipulations designed to achieve a compromise between over- and under-attenuated phenotype.
Taken together, the live-attenuated RSV vaccine approach has shown promise based on current knowledge of cp/ts mutations within the genome, essential/non-essential RSV genes, and structure/function of RSV-encoded genes. The major challenge to this approach remains the need of achieving an appropriate balance between the two priorities of live-attenuated RSV vaccine development (over-attenuation/suboptimal immunogenicity and under-attenuation/bearing pathogenic potential)19.
RSV-derived F and G proteins and their derivatives bearing neutralizing epitopes have undergone preclinical and clinical assessments as non-replicating protein subunit vaccines. The first of such preclinical studies utilized RSV F and G proteins that were purified from RSV-infected cell cultures and F and F/G chimeric proteins produced in baculovirus-infected insect cells or transfected mammalian cell lines39, 40 Rodents immunized with these preparations generated antibodies similar to those observed for FI-RSV in that despite recognition of RSV antigen in ELISAs, the resulting antibodies were poorly neutralizing41, 42. In addition, rodents immunized with such RSV-encoded proteins and subsequently challenged 3–6 months later developed lung pathology similar to those observed for FI-RSV42. To circumvent the potential deleterious consequences of subunit vaccination, several groups have utilized various adjuvants, including those specific for various Toll-like receptors (TLRs) (e.g. monophosphoryl lipid A (MPL) for TLR-4, CpG oligonucleotides for TLR-9) and have reported that in some cases, the use of adjuvants can significantly alter the immunogenicity and adverse effects of subunit vaccines43, 44. Of relevance is the recent observation that TLR agonists may play a significant role in the affinity maturation of antibodies against RSV-encoded proteins45. Thus, in principle, appropriate TLR stimulation during vaccination with RSV subunit preparations may generate high-affinity anti-RSV antibodies that recognize appropriate epitopes in non-denatured configurations.
With respect to clinical evaluation of RSV subunit vaccine candidates, several preparations of RSV-encoded proteins have been tested. Such preparations include: PFP (purified F protein) derivatives (PFP-1, -2, and -3); FG chimeric protein; a co-purified formulation of F, G, and M proteins, and a bacterially derived RSV G derivative (BBG2Na). Such efforts are briefly described below.
The PFP series have been purified from RSV-infected Vero cells and successive versions are comprised of higher purity of RSV F (i.e. 90–95% F for PFP-1 vs. > 98% for PFP-2 and -3)46, 47. PFP-1 has been tested in RSV-seropositive children in two clinical trials involving 24–48 month old and 18–36 month old, RSV-seropositive children47, 48. In these studies, no obvious adverse events were evident and ≥ 4-fold increase in RSV-neutralizing antibody titer was observed in a majority of subjects. A single priming intramuscular dose of PFP-2 (50 µg) was administered to 1–12 year old children with bronchopulmonary dysplasia (n = 10) or 1–8 year olds with cystic fibrosis (n = 17); in this study, the majority of participants exhibited ≥ 4 fold increase in RSV-neutralizing antibody titers49, 50. PFP-3 has been tested as a single 30 µintramuscular vaccination dose in a phase II study among 143 1–12 year old children with cystic fibrosis51. As in the case of PFP-2, PFP-3 also elicited a ≥ 4-fold increase in RSV neutralizing titers. However, the rate of RSV infection after vaccination was not significantly different between the vaccinated and control groups. In two studies involving elderly adults, a single 50 µg dose of PFP-2 was also immunogenic in 61% (out of 33 subjects > 60 years old) and 47% (of 36 frail elderly adults > 65 years old)52, 53. Lastly, a single 20 µg dose of PFP-2 administered to 20 pregnant women was well tolerated54. Although the vaccine led to a ≥4-fold increase in anti-F antibodies in the vast majority of vaccinees and their infants up to 6 months following birth, only 10% of the study subjects had a corresponding ≥ 4-fold increase in RSV neutralizing antibody titers.
BBG2Na, a bacterially derived protein bearing aa 130–230 of subgroup A RSV G protein fused to the albumin-binding domain of streptococcal protein G, has also undergone preclinical and clinical evaluation. In rodent models, BBG2Na conferred protection against RSV even though it generated modest levels of RSV-neutralizing antibodies55. However, in limited primate studies, this antigen was associated with limited viral challenge protection and also with Th2-biased immune response56. Among healthy young adults and elderly adults, this antigen was also well tolerated in phase II studies19. However, in a phase III study involving elderly adults, anti-RSV serum antibody titers declined significantly within four weeks after vaccination and limited number of unanticipated adverse events have been reported.
With respect to other clinical trials with RSV subunit/protein-derived vaccine candidates, limited data are available. For FG chimeric protein testing, phase I and II studies involving its administration with various adjuvants have been started but not formally reported19. In one study, a co-purified formulation of RSV F, G, and M proteins were emulsified in one of two adjuvants (aluminum hydroxide and poly(di[carboxylatophenoxy]phosphazene; PCPP) and administered to healthy adults (total n = 70)57. In this study, both vaccine formulations induced similar levels of ≥ 4-fold increase in RSV neutralizing antibody titers and collectively in > 80% of the study population. In a large-scale phase II study in which 1169 elderly adults with cardiopulmonary conditions, the RSV F, G and M-containing vaccine was immunogenic; a greater proportion of subjects immunized with non-adjuvanted vaccine had ≥ 4-fold increase in RSV neutralizing antibody titers as compared to that in the group challenged with alum-containing vaccine candidate (168/383 (44%) vs. 129/400 (33%))58.
Short peptides derived from RSV F and G proteins have been tested in animal models. In the case of short, RSV F-derived peptides, limited immunogenicity was seen59. Recent data suggest that in mice, administration of bacterially derived short fragments of RSV F (including aa 255–278 and 412–524) fused to the ctxA(2)B cholera holotoxin led to anti-F, RSV-neutralizing antibody response and a modest protective efficacy in mouse RSV challenge studies60, 61. For RSV G, the aa sequence (174–187) derived from the central core of RSV G has been administered to mice; in such experiments, protections against RSV infection was noted despite inefficient RSV neutralizing response62, 63.
An alternative platform for RSV subunit vaccines is virus-like particles (VLPs), which are non-replicating, non-infectious particles derived from virus-encoded proteins64. In the case of human papillomavirus (HPV) VLP-based licensed vaccine, the HPV L1 capsid protein self-assembles into particles that appear morphologically indistinguishable from native HPV virions65. The resulting VLPs elicit strong humoral and cellular immune responses and provide durable protection against HPV. Other virus-encoded proteins, such as the influenza hemaglutinin and the hepatitis B surface antigen (HBSAg), can also form VLPs and in the latter case, have been engineered to contain an RSV-encoded CTL epitope66. Most recently, nanoparticles derived from bacterially derived RSV nucleocapsid proteins have been shown to confer a moderate degree of protection against RSV challenge in rodent models67. Because of their potent immunogenicity, VLPs may be an alternative platform for RSV subunit vaccine provided that appropriate epitopes can be successfully presented.
Several live virus vectors have been generated to express RSV-encoded proteins. Such vectors have included vaccinia virus (mouse-adapted WR strain and the MVA strain) engineered to express RSV F and G as well as adenovirus derivatives expressing RSV F68, 69. In these cases, there was no significant immunogenicity or protective efficacy in primates7072. More recently, genetically engineered varieties of parainfluenza viruses including HPIV3, Sendai virus (SeV), and a chimeric bovine parainfluenza virus (BPIV)/ HPIV3 have been used to express RSV F and G under the control of endogenous PIV gene expression signals; these have the possibility of being developed as a bivalent RSV/PIV vaccine for the pediatric population7376. B/PIV3 expressing RSV F has been shown to be immunogenic and efficacious in RSV protective challenge studies in primates and is currently being evaluated in clinical studies77.
Recent studies have described various strategies to express RSV F and/or G in the context of live bacterial vectors and non-replicating viral vectors. For example, Staphylococcus carnosus, a non-pathogenic bacterium, has been modified to express on its surface three portions of the RSV G protein fused to a fragment of the cholera B subunit protein78. The resulting bacteria have the potential advantage of oral or intranasal administration but were found to provide limited and variable protective efficacy in mouse RSV challenge studies. RSV F and/or G have been expressed in the context on replication-incompetent (i.e. replicon-based) alphavirus vectors, as well as the avian Newcastle disease virus and human rhinovirus type 147982. Most of these viral vectored RSV vaccine candidates are immunogenic and protective to varying degrees in mouse RSV challenge studies.
Through various routes, including intramuscular, intradermal, microparticle “gene gun,” or DNA-carbohydrate/albumin intranasal approaches, immunization of rodents with DNA plasmids encoding RSV F or G proteins has shown that administration of DNA is immunogenic and protective to a limited degree in RSV challenge experiments8386. DNA-based RSV vaccine has the potential to express RSV-encoded proteins in its native structure and possibly do so in the context of immature immune system in infants and thereby overcoming the maternal antibody-associated immunosuppression of anti-RSV response. However, lingering technical challenges for this approach include: the time of onset of immune response, the amount of DNA required to generate a clinically relevant immune response, and the likely need for multiple repeated administration of such DNA molecules.
RSV vaccine development remains a high priority based on the burden of diseases and limited number of licensed prophylactic and therapeutic options. Previous and current efforts involve the development and preclinical/clinical (where appropriate) testing of live attenuated RSV strains, RSV subunit-based proteins, live/non-replicating vector-derived vaccine candidates, and DNA-based approaches. Based on the historical experience with formalin-inactivated RSV vaccine, further studies on RSV vaccine development will likely require continued safety and efficacy monitoring. Since immune response against RSV following natural infection is incomplete, it is possible that two vaccines – one for pediatric, RSV-naïve subjects and another for RSV-infected elderly adults – will be developed.
Acknowledgements
My work is supported by an NIH grant (R21AI076781). I am a co-author of a provisional patent application on the use of human papillomavirus L1 capsid protein and its derivatives as RSV vaccine candidates.
This work was supported by Grant No. AI076781 from the National Institutes of Health.
Footnotes
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
1. Hall CB, McCarthy CA. Respiratory syncytial virus. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practices of Infectious Disease. Vol 6th. Philadelphia: Elsevier Churchill Livingstone; 2004. pp. 2008–2026.
2. Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis. 1991;163:693–698. [PubMed]
3. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the united states. JAMA. 2003;289:179–186. [PubMed]
4. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352:1749–1759. [PubMed]
5. Collins PL, Graham BS. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol. 2008;82:2040–2055. [PMC free article] [PubMed]
6. Taylor G, Stott EJ, Bew M, Fernie BF, Cote PJ. Monoclonal antibodies protect against respiratory syncytial virus. Lancet. 1983;2:976. [PubMed]
7. Walsh EE, Schlesinger JJ, Brandriss MW. Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect Immun. 1984;43:756–758. [PMC free article] [PubMed]
8. Walsh EE, Cote PJ, Fernie BF, Schlesinger JJ, Brandriss MW. Analysis of the respiratory syncytial virus fusion protein using monoclonal and polyclonal antibodies. J Gen Virol. 1986;67(Pt 3):505–513. [PubMed]
9. IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531–537. [PubMed]
10. Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol. 2002;76:5654–5666. [PMC free article] [PubMed]
11. Openshaw PJ, Tregoning JS. Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev. 2005;18:541–555. [PMC free article] [PubMed]
12. Braciale TJ. Respiratory syncytial virus and T cells: Interplay between the virus and the host adaptive immune system. Proceedings of the American Thoracic Society. 2005;2:141–146. [PubMed]
13. Graham BS, Bunton LA, Wright PF, Karzon DT. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest. 1991;88:1026–1033. [PMC free article] [PubMed]
14. Alwan WH, Record FM, Openshaw PJ. CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. comparison with the effects of CD8+ T cells. Clin Exp Immunol. 1992;88:527–536. [PubMed]
15. Tang YW, Graham BS. T cell source of type 1 cytokines determines illness patterns in respiratory syncytial virus-infected mice. J Clin Invest. 1997;99:2183–2191. [PMC free article] [PubMed]
16. Peebles RS, Jr, Graham BS. Pathogenesis of respiratory syncytial virus infection in the murine model. Proc Am Thorac Soc. 2005;2:110–115. [PMC free article] [PubMed]
17. Murphy BR, Sotnikov AV, Lawrence LA, Banks SM, Prince GA. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3–6 months after immunization. Vaccine. 1990;8:497–502. [PubMed]
18. Openshaw PJ, Clarke SL, Record FM. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int Immunol. 1992;4:493–500. [PubMed]
19. Collins PL, Murphy BR. Vaccines against human respiratory syncytial virus. In: Cane PA, editor. Respiratory Syncytial Virus. Amsterdam: Elsevier; 2007. p. 233.
20. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol. 1969;89:435–448. [PubMed]
21. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol. 1969;89:405–421. [PubMed]
22. Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol. 1969;89:449–463. [PubMed]
23. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89:422–434. [PubMed]
24. Murphy BR, Walsh EE. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol. 1988;26:1595–1597. [PMC free article] [PubMed]
25. Peebles RS, Jr, Sheller JR, Collins RD, Jarzecka K, Mitchell DB, Graham BS. Respiratory syncytial virus (RSV)-induced airway hyperresponsiveness in allergically sensitized mice is inhibited by live RSV and exacerbated by formalin-inactivated RSV. J Infect Dis. 2000;182:671–677. [PubMed]
26. Prince GA, Jenson AB, Hemming VG, et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus. J Virol. 1986;57:721–728. [PMC free article] [PubMed]
27. Belshe RB, Van Voris LP, Mufson MA. Parenteral administration of live respiratory syncytial virus vaccine: Results of a field trial. J Infect Dis. 1982;145:311–319. [PubMed]
28. Collins PL, Murphy BR. New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. Proc Am Thorac Soc. 2005;2:166–173. [PMC free article] [PubMed]
29. Friedwald W, Forsyth B, Smith C, Gharpure M, Chanock RM. Low-temperature-grown RS virus in adult volunteers. JAMA. 1968;204:142–146. [PubMed]
30. Wright PF, Karron RA, Belshe RB, et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis. 2000;182:1331–1342. [PubMed]
31. Pringle CR, Filipiuk AH, Robinson BS, Watt PJ, Higgins P, Tyrrell DA. Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers. Vaccine. 1993;11:473–478. [PubMed]
32. Whitehead SS, Firestone CY, Karron RA, et al. Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. J Virol. 1999;73:871–877. [PMC free article] [PubMed]
33. Whitehead SS, Firestone CY, Collins PL, Murphy BR. A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes. Virology. 1998;247:232–239. [PubMed]
34. Juhasz K, Whitehead SS, Boulanger CA, Firestone CY, Collins PL, Murphy BR. The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations. Vaccine. 1999;17:1416–1424. [PubMed]
35. Whitehead SS, Juhasz K, Firestone CY, Collins PL, Murphy BR. Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. J Virol. 1998;72:4467–4471. [PMC free article] [PubMed]
36. Teng MN, Whitehead SS, Bermingham A, et al. Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J Virol. 2000;74:9317–9321. [PMC free article] [PubMed]
37. Karron RA, Wright PF, Belshe RB, et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis. 2005;191:1093–1104. [PubMed]
38. Wright PF, Karron RA, Madhi SA, et al. The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J Infect Dis. 2006;193:573–581. [PubMed]
39. Walsh EE, Hall CB, Briselli M, Brandriss MW, Schlesinger JJ. Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection. J Infect Dis. 1987;155:1198–1204. [PubMed]
40. Wathen MW, Kakuk TJ, Brideau RJ, Hausknecht EC, Cole SL, Zaya RM. Vaccination of cotton rats with a chimeric FG glycoprotein of human respiratory syncytial virus induces minimal pulmonary pathology on challenge. J Infect Dis. 1991;163:477–482. [PubMed]
41. Murphy BR, Sotnikov A, Paradiso PR, et al. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease. Vaccine. 1989;7:533–540. [PubMed]
42. Murphy BR, Sotnikov AV, Lawrence LA, Banks SM, Prince GA. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3–6 months after immunization. Vaccine. 1990;8:497–502. [PubMed]
43. Hancock GE, Heers KM, Pryharski KS, Smith JD, Tiberio L. Adjuvants recognized by toll-like receptors inhibit the induction of polarized type 2 T cell responses by natural attachment (G) protein of respiratory syncytial virus. Vaccine. 2003;21:4348–4358. [PubMed]
44. Prince GA, Denamur F, Deschamps M, et al. Monophosphoryl lipid A adjuvant reverses a principal histologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease. Vaccine. 2001;19:2048–2054. [PubMed]
45. Delgado MF, Coviello S, Monsalvo AC, et al. Lack of antibody affinity maturation due to poor toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med. 2009;15:34–41. [PMC free article] [PubMed]
46. Belshe RB, Anderson EL, Walsh EE. Immunogenicity of purified F glycoprotein of respiratory syncytial virus: Clinical and immune responses to subsequent natural infection in children. J Infect Dis. 1993;168:1024–1029. [PubMed]
47. Tristram DA, Welliver RC, Mohar CK, Hogerman DA, Hildreth SW, Paradiso P. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18–36 months old. J Infect Dis. 1993;167:191–195. [PubMed]
48. Paradiso PR, Hildreth SW, Hogerman DA, et al. Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old. Pediatr Infect Dis J. 1994;13:792–798. [PubMed]
49. Piedra PA, Grace S, Jewell A, et al. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr Infect Dis J. 1996;15:23–31. [PubMed]
50. Groothuis JR, King SJ, Hogerman DA, Paradiso PR, Simoes EA. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J Infect Dis. 1998;177:467–469. [PubMed]
51. Piedra PA, Cron SG, Jewell A, et al. Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: A multi-center trial in children with cystic fibrosis. Vaccine. 2003;21:2448–2460. [PubMed]
52. Falsey AR, Walsh EE. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine. 1996;14:1214–1218. [PubMed]
53. Falsey AR, Walsh EE. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine. 1997;15:1130–1132. [PubMed]
54. Munoz FM, Piedra PA, Glezen WP. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine. 2003;21:3465–3467. [PubMed]
55. Power UF, Plotnicky-Gilquin H, Huss T, et al. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology. 1997;230:155–166. [PubMed]
56. de Waal L, Power UF, Yuksel S, et al. Evaluation of BBG2Na in infant macaques: Specific immune responses after vaccination and RSV challenge. Vaccine. 2004;22:915–922. [PubMed]
57. Ison MG, Mills J, Openshaw P, Zambon M, Osterhaus A, Hayden F. Current research on respiratory viral infections: Fourth international symposium. Antiviral Res. 2002;55:227–278. [PubMed]
58. Falsey AR, Walsh EE, Capellan J, et al. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals. J Infect Dis. 2008;198:1317–1326. [PubMed]
59. Trudel M, Stott EJ, Taylor G, et al. Synthetic peptides corresponding to the F protein of RSV stimulate murine B and T cells but fail to confer protection. Arch Virol. 1991;117:59–71. [PubMed]
60. Singh SR, Dennis VA, Carter CL, Pillai SR. Respiratory syncytial virus recombinant F protein (residues 255–278) induces a helper T cell type 1 immune response in mice. Viral Immunol. 2007;20:261–275. [PubMed]
61. Singh SR, Dennis VA, Carter CL, et al. Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model. Vaccine. 2007;25:6211–6223. [PMC free article] [PubMed]
62. Trudel M, Nadon F, Seguin C, Binz H. Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G-glycoprotein. Virol. 1991;185:749–757. [PubMed]
63. Bastien N, Trudel M, Simard C. Complete protection of mice from respiratory syncytial virus infection following mucosal delivery of synthetic peptide vaccines. Vaccine. 1999;17:832–836. [PubMed]
64. Jennings GT, Bachmann MF. The coming of age of virus-like particle vaccines. Biol Chem. 2008;389:521–536. [PubMed]
65. Siddiqui MA, Perry CM. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (gardasil) Drugs. 2006;66:1263–1271. discussion 1272-3. [PubMed]
66. Woo WP, Doan T, Herd KA, Netter HJ, Tindle RW. Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes. J Virol. 2006;80:3975–3984. [PMC free article] [PubMed]
67. Roux X, Dubuquoy C, Durand G, et al. Sub-nucleocapsid nanoparticles: A nasal vaccine against respiratory syncytial virus. PLoS ONE. 2008;3:e1766. [PMC free article] [PubMed]
68. Connors M, Collins PL, Firestone CY, Murphy BR. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J Virol. 1991;65:1634–4637. [PMC free article] [PubMed]
69. Wyatt LS, Whitehead SS, Venanzi KA, Murphy BR, Moss B. Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. Vaccine. 1999;18:392–397. [PubMed]
70. Collins PL, Purcell RH, London WT, Lawrence LA, Chanock RM, Murphy BR. Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus. Vaccine. 1990;8:164–168. [PubMed]
71. Crowe JE, Jr, Collins PL, London WT, Chanock RM, Murphy BR. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine. 1993;11:1395–1404. [PubMed]
72. de Waal L, Wyatt LS, Yuksel S, et al. Vaccination of infant macaques with a recombinant modified vaccinia virus ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology. Vaccine. 2004;22:923–926. [PubMed]
73. Takimoto T, Hurwitz JL, Zhan X, et al. Recombinant sendai virus as a novel vaccine candidate for respiratory syncytial virus. Viral Immunol. 2005;18:255–266. [PubMed]
74. Tang RS, Schickli JH, MacPhail M, et al. Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity. J Virol. 2003;77:10819–10828. [PMC free article] [PubMed]
75. Schmidt AC, McAuliffe JM, Murphy BR, Collins PL. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J Virol. 2001;75:4594–4603. [PMC free article] [PubMed]
76. Schmidt AC, Wenzke DR, McAuliffe JM, et al. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. J Virol. 2002;76:1089–1099. [PMC free article] [PubMed]
77. Tang RS, MacPhail M, Schickli JH, et al. Parainfluenza virus type 3 expressing the native or soluble fusion (F) protein of respiratory syncytial virus (RSV) confers protection from RSV infection in african green monkeys. J Virol. 2004;78:11198–11207. [PMC free article] [PubMed]
78. Cano F, Plotnicky-Gilquin H, Nguyen TN, et al. Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface-displayed RSV-peptides. Vaccine. 2000;18:2743–2752. [PubMed]
79. Mok H, Lee S, Utley TJ, et al. Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. J Virol. 2007;81:13710–13722. [PMC free article] [PubMed]
80. Elliott MB, Chen T, Terio NB, et al. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune esponses in BALB/c mice and functional serum antibodies in rhesus macaques. Vaccine. 2007;25:7132–7144. [PubMed]
81. Martinez-Sobrido L, Gitiban N, Fernandez-Sesma A, et al. Protection against respiratory syncytial virus by a recombinant newcastle disease virus vector. J Virol. 2006;80:1130–1139. [PMC free article] [PubMed]
82. Dollenmaier G, Mosier SM, Scholle F, Sharma N, McKnight KL, Lemon SM. Membrane-associated respiratory syncytial virus F protein expressed from a human rhinovirus type 14 vector is immunogenic. Virology. 2001;281:216–230. [PubMed]
83. Li X, Sambhara S, Li CX, et al. Protection against respiratory syncytial virus infection by DNA immunization. J Exp Med. 1998;188:681–688. [PMC free article] [PubMed]
84. Li X, Sambhara S, Li CX, et al. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate. Virology. 2000;269:54–65. [PubMed]
85. Kumar M, Behera AK, Lockey RF, et al. Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum Gene Ther. 2002;13:1415–1425. [PubMed]
86. Bembridge GP, Rodriguez N, Garcia-Beato R, Nicolson C, Melero JA, Taylor G. Respiratory syncytial virus infection of gene gun vaccinated mice induces Th2-driven pulmonary eosinophilia even in the absence of sensitisation to the fusion (F) or attachment (G) protein. Vaccine. 2000;19:1038–1046. [PubMed]